Application of His-Purkinje conduction system pacing in patients with giant right atrium
盛夏,潘轶文,傅国胜,王敏,杨莹,孙雅逊,徐添添,张杰芳
DOI: https://doi.org/10.3760/cma.j.cn.113859-20210714-00148
2021-01-01
Abstract:Objective:To explore the clinical application of His-Purkinje conduction system pacing (HPCSP) in patients with giant right atrium.Methods:We consecutively recruited 155 patients with giant right atrium scheduled to have pacemaker implantation from January 2017 to December 2019 in Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, and explored the parameter changes and clinical outcomes. His bundle pacing (HBP) was performed in 53 patients [including male 35, with an average age of (69.5±11.7) years] , and left bundle branch pacing (LBBP) was performed in 72 patients [including male 44, with an average age of (71.3±8.6) years] , and right ventricular pacing (RVP) was performed in 30 patients [including male 20, with an average age of (69.5±10.3) years] . The parameters such as lead threshold, perception, impedance, and echocardiographic indexes such as left ventricular ejection fraction (LVEF) , left ventricular end diastolic diameter (LVEDD) and right ventricular systolic pressure (RVSP) were evaluated and compared during operation and follow-up.Results:The baseline demography was not significantly different among three groups.①The pacing success rates were 84.9% (45/53) , 94.4% (68/72) and 100% in three groups respectively. ②Compared to RVP pacing, HBP pacing had a significant difference in threshold ( P=0.04) and amplitude (P=0.01) . ③All the parameters were remained stable during follow-up period. Both LBBP and HBP patients had similar LVEF and LVEDD without significant change compared with baseline. Compared to baseline, RVSP in HBP group and LBBP group was significantly lower than baseline [HBP group: (44.0±19.9) mmHg vs. (50.1±25.4) mmHg, P=0.04; LBBP group: (41.8±15.7) mmHg vs. (51.7±19.8) mmHg, P=0.03] . There was no significant difference in LVEDD and RVSP in RVP group, while LVEF was significantly decreased [ (45.1%±18.2%) vs. (50.8%±19.9%) , P=0.04] . Conclusion:HPCSP is feasible and safe for patients with giant right atrium. Unique techniques such as sheath remolding or supported by the left ventricular lead delivery system could increase the success rate of HPCSP in patients with giant right atrium.